Effects of Creatine Monohydrate Augmentation on Brain Metabolic and Network Outcome Measures in Women With Major Depressive Disorder

BACKGROUND Creatine monohydrate (creatine) augmentation has the potential to accelerate the clinical responses to and enhance the overall efficacy of selective serotonin reuptake inhibitor treatment in women with major depressive disorder (MDD). Although it has been suggested that creatine augmentation may involve the restoration of brain energy metabolism, the mechanisms underlying its antidepressant efficacy are unknown. METHODS In a randomized, double-blind, placebo-controlled trial, 52 women with MDD were assigned to receive either creatine augmentation or placebo augmentation of escitalopram; 34 subjects participated in multimodal neuroimaging assessments at baseline and week 8. Age-matched healthy women (n = 39) were also assessed twice at the same intervals. Metabolic and network outcomes were measured for changes in prefrontal N-acetylaspartate and changes in rich club hub connections of the structural brain network using proton magnetic resonance spectroscopy and diffusion tensor imaging, respectively. RESULTS We found MDD-related metabolic and network dysfunction at baseline. Improvement in depressive symptoms was greater in patients receiving creatine augmentation relative to placebo augmentation. After 8 weeks of treatment, prefrontal N-acetylaspartate levels increased significantly in the creatine augmentation group compared with the placebo augmentation group. Increment in rich club hub connections was also greater in the creatine augmentation group than in the placebo augmentation group. CONCLUSIONS N-acetylaspartate levels and rich club connections increased after creatine augmentation of selective serotonin reuptake inhibitor treatment. Effects of creatine administration on brain energy metabolism and network organization may partly underlie its efficacy in treating women with MDD.

[1]  P. Renshaw,et al.  Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study. , 2011, Journal of affective disorders.

[2]  P. Renshaw,et al.  Chronic Creatine Supplementation Alters Depression-like Behavior in Rodents in a Sex-Dependent Manner , 2010, Neuropsychopharmacology.

[3]  Hyporeactivity of ventral striatum towards incentive stimuli in unmedicated depressed patients normalizes after treatment with escitalopram , 2012, Journal of psychopharmacology.

[4]  Xiaoqi Huang,et al.  Disrupted Brain Connectivity Networks in Drug-Naive, First-Episode Major Depressive Disorder , 2011, Biological Psychiatry.

[5]  D. Rueckert,et al.  Rich-club organization of the newborn human brain , 2014, Proceedings of the National Academy of Sciences.

[6]  Olaf Sporns,et al.  Complex network measures of brain connectivity: Uses and interpretations , 2010, NeuroImage.

[7]  F. Gomez-Pinilla,et al.  Coupling energy metabolism with a mechanism to support brain-derived neurotrophic factor-mediated synaptic plasticity , 2006, Neuroscience.

[8]  S. Provencher.  Automatic quantitation of localized in vivo 1H spectra with LCModel , 2001, NMR in biomedicine.

[9]  Anders M. Dale,et al.  An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest , 2006, NeuroImage.

[10]  Ellen Frank,et al.  Major depressive disorder: new clinical, neurobiological, and treatment perspectives , 2012, The Lancet.

[11]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[12]  Clare E. Mackay,et al.  A Systematic Review of Diffusion Tensor Imaging Studies in Affective Disorders , 2009, Biological Psychiatry.

[13]  J. P. Hamilton,et al.  Anomalous Gray Matter Structural Networks in Major Depressive Disorder , 2013, Biological Psychiatry.

[14]  D. Pizzagalli.  Frontocingulate Dysfunction in Depression: Toward Biomarkers of Treatment Response , 2011, Neuropsychopharmacology.

[15]  Xiong Cao,et al.  Astrocyte-derived ATP modulates depressive-like behaviors , 2013, Nature Medicine.

[16]  Perry F. Renshaw,et al.  Brain Bioenergetics and Response to Triiodothyronine Augmentation in Major Depressive Disorder , 2008, Biological Psychiatry.

[17]  P. Matthews,et al.  Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. , 2004, The American journal of psychiatry.

[18]  M. Beal,et al.  Creatine and Its Potential Therapeutic Value for Targeting Cellular Energy Impairment in Neurodegenerative Diseases , 2008, NeuroMolecular Medicine.

[19]  P. Renshaw,et al.  Altered prefrontal glutamate-glutamine-gamma-aminobutyric acid levels and relation to low cognitive performance and depressive symptoms in type 1 diabetes mellitus. , 2009, Archives of general psychiatry.

[20]  O. Sporns,et al.  The economy of brain network organization , 2012, Nature Reviews Neuroscience.

[21]  Klaas Nicolay,et al.  1H MR spectroscopy of the brain: absolute quantification of metabolites. , 2006, Radiology.

[22]  O. Sporns,et al.  Rich-Club Organization of the Human Connectome , 2011, The Journal of Neuroscience.

[23]  Dimitrios Kapogiannis,et al.  Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease , 2011, The Lancet Neurology.

[24]  P. Renshaw,et al.  Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study , 2015, Journal of dual diagnosis.

[25]  J. Andrews-Hanna,et al.  Large-Scale Network Dysfunction in Major Depressive Disorder: A Meta-analysis of Resting-State Functional Connectivity. , 2015, JAMA psychiatry.

[26]  P. Renshaw,et al.  Application of Magnetic Resonance Spectroscopic Imaging to Addiction Research , 2013 .

[27]  P. V. van Zijl,et al.  Three‐dimensional tracking of axonal projections in the brain by magnetic resonance imaging , 1999, Annals of neurology.

[28]  Sek Won Kong,et al.  Multinuclear magnetic resonance spectroscopy of high-energy phosphate metabolites in human brain following oral supplementation of creatine-monohydrate , 2003, Psychiatry Research: Neuroimaging.

[29]  J. Hennen.  Statistical methods for longitudinal research on bipolar disorders. , 2003, Bipolar disorders.

[30]  L. Williams,et al.  Abnormal Structural Networks Characterize Major Depressive Disorder: A Connectome Analysis , 2014, Biological Psychiatry.

[31]  P. Andrews,et al.  Is serotonin an upper or a downer? The evolution of the serotonergic system and its role in depression and the antidepressant response , 2015, Neuroscience & Biobehavioral Reviews.

[32]  S. Strakowski.  Bioenergetics for depression: something different for depression. , 2012, The American journal of psychiatry.

[33]  P. Renshaw,et al.  Prefrontal cortical deficits in type 1 diabetes mellitus: brain correlates of comorbid depression. , 2012, Archives of general psychiatry.

[34]  B. Roth,et al.  Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression∗ ∗ See accompanying Editorial, in this issue. , 1999, Biological Psychiatry.

[35]  W. Drevets.  Prefrontal Cortical‐Amygdalar Metabolism in Major Depression , 1999, Annals of the New York Academy of Sciences.

[36]  P F Renshaw,et al.  Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: a phosphorous-31 magnetic resonance spectroscopy study. , 1997, The American journal of psychiatry.

[37]  O. Sporns,et al.  High-cost, high-capacity backbone for global brain communication , 2012, Proceedings of the National Academy of Sciences.

[38]  M. F. Beal,et al.  Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG , 2006, Neurology.

[39]  K. Cosgrove,et al.  Evolving Knowledge of Sex Differences in Brain Structure, Function, and Chemistry , 2007, Biological Psychiatry.

[40]  S. Lui,et al.  Is depression a disconnection syndrome? Meta-analysis of diffusion tensor imaging studies in patients with MDD. , 2013, Journal of psychiatry & neuroscience : JPN.

[41]  A. Arnsten,et al.  Estrogen mediates sex differences in stress-induced prefrontal cortex dysfunction , 2004, Molecular Psychiatry.

[42]  B. Lebowitz,et al.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. , 2006, The American journal of psychiatry.

[43]  J. Bustillo.  Use of proton magnetic resonance spectroscopy in the treatment of psychiatric disorders: a critical update , 2013, Dialogues in clinical neuroscience.

[44]  Bethany K. Bracken,et al.  T 2 relaxation effects on apparent N-acetylaspartate concentration in proton magnetic resonance studies of schizophrenia , 2013, Psychiatry Research: Neuroimaging.

[45]  R. Simes,et al.  An improved Bonferroni procedure for multiple tests of significance , 1986 .

[46]  P. Renshaw,et al.  A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder. , 2012, The American journal of psychiatry.

[47]  Martin Lepage,et al.  Medial prefrontal cortex activity during memory encoding of pictures and its relation to symptomatic improvement after citalopram treatment in patients with major depression. , 2010, Journal of psychiatry & neuroscience : JPN.

[48]  M. Mattson,et al.  Mitochondria in Neuroplasticity and Neurological Disorders , 2008, Neuron.

[49]  Joaquín Goñi,et al.  Abnormal rich club organization and functional brain dynamics in schizophrenia. , 2013, JAMA psychiatry.

[50]  P. Renshaw,et al.  T2 relaxation time abnormalities in bipolar disorder and schizophrenia , 2010, Magnetic resonance in medicine.

[51]  O. Sporns,et al.  Structural and Functional Aspects Relating to Cost and Benefit of Rich Club Organization in the Human Cerebral Cortex , 2013, Cerebral cortex.

[52]  Oded Gonen,et al.  Metabolite ratios to assumed stable creatine level may confound the quantification of proton brain MR spectroscopy. , 2003, Magnetic resonance imaging.

[53]  P F Renshaw,et al.  Multinuclear magnetic resonance spectroscopy studies of brain purines in major depression. , 2001, The American journal of psychiatry.